CS
IGMS

Credit Suisse’s IGM Biosciences IGMS Stock Holding History

Credit Suisse’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,607
Closed -$97.9K – 3157
2023
Q2 		$97.9K Sell
10,607
-604
-5% -$6.77K ﹤0.01% 3133
2023
Q1 		$154K Buy
11,211
+2,823
+34% +$58.4K ﹤0.01% 3160
2022
Q4 		$143K Buy
8,388
+2,944
+54% +$58.9K ﹤0.01% 3265
2022
Q3 		$124K Buy
5,444
+54
+1% +$1.09K ﹤0.01% 3393
2022
Q2 		$98K Buy
+5,390
New +$96.1K ﹤0.01% 3533
2021
Q4 		– Sell
-4,308
Closed -$283K – 4582
2021
Q3 		$283K Buy
4,308
+85
+2% +$6.5K ﹤0.01% 4105
2021
Q2 		$351K Sell
4,223
-1,871
-31% -$139K ﹤0.01% 4032
2021
Q1 		$468K Sell
6,094
-10,904
-64% -$993K ﹤0.01% 3813
2020
Q4 		$1.5M Buy
16,998
+4,643
+38% +$326K ﹤0.01% 3040
2020
Q3 		$911K Sell
12,355
-1,133
-8% -$67.1K ﹤0.01% 3002
2020
Q2 		$985K Buy
+13,488
New +$819K ﹤0.01% 2917

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Credit Suisse's IGMS Position: Q3 2023 in Review

Credit Suisse sold out of IGM Biosciences (IGMS) in Q3 2023, closing a stake of 10,607 shares — an estimated $97.9K sold.

Credit Suisse first reported a position in IGMS in Q2 2020 and held it in 11 quarters. The position peaked at $1.5M in Q4 2020. 79 funds tracked by Wall St. Rank hold IGMS as of Q3 2023.

  • Credit Suisse reported no remaining IGM Biosciences position as of Q3 2023 after selling out during the quarter.
  • Credit Suisse sold 10,607 IGM Biosciences shares in Q3 2023, an estimated $97.9K.
  • Credit Suisse first reported a position in IGM Biosciences in Q2 2020 and held it in 11 quarters.
  • Credit Suisse's IGM Biosciences position peaked at $1.5M in Q4 2020.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.